Fluxergy announced that it utilized in-kind Diagnostics Development Services from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance molecular testing and sample preparation capabilities on the Fluxergy Platform.
Under NIAID's suite of preclinical services, NIAID-funded contractors will evaluate rapid nucleic acid extraction and purification methods compatible with the Fluxergy Test Card, with the goal of achieving high sensitivity, sample-to-answer molecular tests to be developed for gram-negative and fungal pathogens that cause sexually transmitted infections and bacterial and fungal vaginosis. These integrated extraction capabilities will be required for the development of Fluxergy's sexually transmitted infection (STI) test and comprehensive vaginosis test.
Many healthcare providers use syndromic management to diagnose and prescribe treatment to patients, leading to inadequate treatment or eventual antimicrobial resistance. By simplifying the workflow and lowering the cost of testing, point-of-care diagnostics can provide a solution to these current issues in STI management.
